Opinion

Video

ASH 2023 Updates on Frontline Therapies in FL

Author(s):

Grzegorz S. Nowakowski, MD,Jennifer Crombie, MD

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

Related Videos
Guru P. Sonpavde, MD
Shaji Kumar, MD
Peter Forsyth, MD
Minoo Battiwalla, MD, MS
Richard Kim, MD, Moffitt Cancer Center
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Related Content
David Liu, MD, MPH
December 3rd 2024

Predictive Tool for Melanoma Could Guide Immunotherapy Choices

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

OncLive’s November Roundup of Key FDA Approvals in Oncology
December 3rd 2024

OncLive’s November Roundup of Key FDA Approvals in Oncology

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Cancer / Image credit: Cornflakesei – stock.adobe.com
December 2nd 2024

Moffitt Study Shows How Cancer Cell Death May Harm the Immune System and Promote Tumor Growth

Peter Martin, MD
December 2nd 2024

BTK Inhibitor–Based Combinations Represent the Future of MCL Management